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Abstract
Background: Patients with breast cancer have an increased risk of developing subsequent breast cancers. It is
important to distinguish whether these tumours are de novo or recurrences of the primary tumour in order to guide
the appropriate therapy. Our aim was to investigate the use of DNA methylation profiling and array comparative
genomic hybridization (aCGH) to determine whether the second tumour is clonally related to the first tumour.
Methods: Methylation-sensitive high-resolution melting was used to screen promoter methylation in a panel of 13
genes reported as methylated in breast cancer (RASSF1A, TWIST1, APC, WIF1, MGMT, MAL, CDH13, RARβ, BRCA1, CDH1,
CDKN2A, TP73, and GSTP1) in 29 tumour pairs (16 ipsilateral and 13 contralateral). Using the methylation profile of these
genes, we employed a Bayesian and an empirical statistical approach to estimate clonal relationship. Copy number
alterations were analysed using aCGH on the same set of tumour pairs.
Results: There is a higher probability of the second tumour being recurrent in ipsilateral tumours compared with
contralateral tumours (38 % versus 8 %; p <0.05) based on the methylation profile. Using previously reported
recurrence rates as Bayesian prior probabilities, we classified 69 % of ipsilateral and 15 % of contralateral tumours as
recurrent. The inferred clonal relationship results of the tumour pairs were generally concordant between methylation
profiling and aCGH.
Conclusion: Our results show that DNA methylation profiling as well as aCGH have potential as diagnostic tools in
improving the clinical decisions to differentiate recurrences from a second de novo tumour.
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Background
Patients with breast cancer are known to have a higher
risk of developing a second breast tumour either in the
affected (ipsilateral) or unaffected (contralateral) breast
[1, 2]. When the second tumour is detected, it is import-
ant to determine whether the tumour is a de novo (new
primary) tumour or a recurrence of the first tumour [3,
4] as the tumour staging and management for the pa-
tient will be different [5]. A recurrent breast tumour is
known to be a predictor of developing breast metastasis
and is associated with poor survival [6, 7], whereas a
new primary may have a better outcome depending on
the pathological features of the tumour [8].
Currently, histopathological features and clinical charac-
teristics are most commonly used to determine the clonal
origin of the tumours. These include histological type, de-
gree of differentiation, presence of an in situ component,
evidence for metastatic spread and the interval between
tumour onsets [3]. However, tumours of distinct clonal
origins may still have very similar histological features.
The use of molecular analysis can supply additional
criteria to distinguish de novo second tumours from re-
current tumours. Goldstein et al. demonstrated that
whereas six out of eight ipsilateral sample pairs (75 %)
were clonally different using a loss of heterozygosity
(LOH) assay, the morphology of the tumour pairs was
similar [9]. They also found that approximately 42 % of
sample pairs had discrepancies between histopathological
classification and molecular classification using LOH pat-
terns. Thus, using histopathological features and clinical
characteristics alone may not correctly identify the rela-
tionship between de novo and recurrent breast cancer [9].
Recently, several other molecular methodologies have been
assessed for their usefulness in determining the clonal rela-
tionship of the tumours. For example, microsatellite in-
stability patterns [10–13], the pattern of X chromosome
inactivation [14], and TP53 mutations [15] have been used.
However, the best differentiation between de novo and re-
current tumours to date has been given by allelic imbal-
ance profiles that result from LOH and tumour
heteroploidy as measured by aCGH [10, 12, 13, 16].
DNA methylation changes are widespread in cancer and
as methylation patterns are often clonally inherited [17],
they can also be used to determine the clonal relationship
of tumours. It is expected that tumours of the same clonal
origin will have closely related DNA methylation patterns
and profiles. In this study, we set out to compare DNA
methylation profiling and aCGH as tools to distinguish
between de novo and recurrent tumours.
Methods
Sample collection and DNA preparation
Formalin-fixed, paraffin-embedded (FFPE) samples for
16 pairs of ipsilateral and 13 pairs of contralateral breast
cancers diagnosed from 1997 to 2007 were obtained
from the St. George Hospital, Sydney, Australia. Ethics
approval was granted by St. George Hospital Human
Research Ethics Committee (07/60) with a waiver of in-
formed consent to obtain archival samples. In addition
our study complies with the current laws of Australia
and ethics approval was obtained from the Peter
MacCallum Cancer Centre Ethics Committee (03/90).
Each pair included the primary tumour and the second
tumour. The de-identified haematoxylin-eosin stained
sections were reviewed by a pathologist and representa-
tive tumour areas were marked and needle-
macrodissected and genomic DNA was extracted by 3
days incubation at 56 °C in buffer ATL (Qiagen, Hilden,
Germany) with 20 mg/μL proteinase K (Qiagen) added
daily, followed by QIAamp DNA Blood Mini Kit
(Qiagen) spin columns according to the manufacturer’s
instructions.
Bisulfite modification
Genomic DNA (500 ng) was bisulfite modified using the
MethylEasy™ Xceed (Human Genetic Signatures, North
Ryde, Australia) according to the manufacturer’s instruc-
tions. The modified DNA was eluted twice in 25 μL of
EB buffer. CpGenome™ Universal Methylated DNA
(Chemicon/Millipore, Billerica, MA) and peripheral
blood mononuclear DNA were used as the methylated
and unmethylated controls, respectively. DNA methy-
lation standards (5, 10, 25 and 50 %) made by dilut-
ing the fully methylated control in the unmethylated
DNA were used as controls. Whole-genome amplifi-
cation (WGA) was also used to make a fully
unmethylated control and performed as described
previously [18].
Methylation-sensitive high-resolution melting (MS-HRM)
MS-HRM was used to detect methylation in bisulfite
modified samples according to the sequence-
dependent thermostability in which the level and
presence of heterogeneous methylation can be de-
tected [19, 20]. A panel of 13 genes that have been
reported to be methylated in breast cancer (RASSF1A,
TWIST1, CDH13, APC, MAL, GSTP1, WIF1, RARβ,
BRCA1, CDKN2A, TP73, CDH1 and MGMT) was
chosen for screening the breast carcinoma samples.
MLH1, which is not methylated in breast cancer, was in-
cluded as a negative control for methylation. MS-HRM
primers were used as previously described [21, 22] ex-
cept for CDH13 and GSTP1. All MS-HRM assays
were designed to amplify amplicon sizes around
100 bp to enable amplification from the majority of
FFPE samples. Primers were designed according to
the principles described previously [23]. The CDH13
MS-HRM primers were 5’-TxTGGTTTTTACGGA
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AAATATGTTTAGTGTA-3’ (forward) and 5’-AAT
TCTCGACTACATTTTATCCGACTAAAA-3’ (reverse).
The 93 bp amplicon (GenBank AC092351 nucleotides
82660620–712) contains six CpGs. The GSTP1 MS-HRM
primers were 5’-GGGGCGGGATTATTTTTATAAGG
TT-3’ (forward) and 5’-GAATTAACCCCATACTAA
AAACTCTAAACC-3’ (reverse). The 140 bp amplicon
(GenBank AP001184, nucleotides 67351239–337)
contains 14 CpGs.
PCR amplification and high-resolution melting ana-
lysis were performed on the Rotor-Gene Q (Qiagen).
PCR conditions for each gene are described in Table 1.
PCR was performed using a final volume of 20 μL.
The reaction mixture consisted of 1 × PCR buffer
(Qiagen), 2.5–4.0 mmol/L of MgCl2, 200 μmol/L of
each dNTP, forward and reverse primers, 5 μmol/L of
SYTO9 intercalating dye (Invitrogen, Carlsbad, CA), 0.5U
of HotStarTaq DNA polymerase (Qiagen) and 10 ng of bi-
sulfite modified DNA. HRM was performed directly after
PCR amplification. HRM consisted of an inactivation step
at 97 °C for 1 min, rapid cooling to 72 °C (or 69 °C), then
melting of the sample from 72 °C to 95 °C with
temperature rising by 0.2 °C per second and holding for
1 s after each stepwise increment for all assays. In each
assay, fully methylated, WGA DNA (unmethylated), dif-
ferent DNA methylation percentage dilution standards
and no template controls were also performed. All assays
were performed in duplicate.
Methylation scoring
Methylation for each gene was considered positive when
it was above 10 %. Setting a cut off point is important
for methylation scoring as low-level endogenous methy-
lation may also be found in normal breast tissue. This
was observed in some patient matched normal breast
tissues, where low levels of methylation (less than 10 %)
can be detected for some genes in these matched normal
breast tissues (KTH, TM, AD unpublished results). Sam-
ples giving non-reproducible melting profiles and late
PCR amplification were scored as uninformative. Methyla-
tion was independently scored by KTH and TM, with a
third opinion from AD where scoring was discrepant.
Analysis of DNA methylation data
The assumption was made that due to the clonal in-
heritance of methylation, clonally related tumours
should have methylation patterns that closely resem-
ble each other. Previous reports have shown that
methylation levels increase during tumour progression
in breast cancer (i.e., in situ carcinoma to invasive
carcinoma) [24]. Therefore, the further assumption
was made that an unmethylated marker in a primary
tumour has a higher probability to be methylated in a
clonally related second tumour than a methylated
marker becoming unmethylated.
Log odds ratios were calculated for each pair of tu-
mours as a measurement of likelihood of recurrence
using methylation data. In the following formulas, R
stands for recurrence, i.e., the two given tumours
come from the same origin; R for non-recurrence,
i.e., different origins; M represents methylated; and M
represents unmethylated. pi represents the probability
of gene i being methylated, where the values of pi or
each of the 13 genes have been estimated from the
literature (see below). Thus, using pi, the probabilities
of a gene being A) methylated in both tumours, B)
unmethylated in both tumours and C) methylated in
only one of the tumours can be calculated, condi-
tional on recurrence/non-recurrence.












APC 2.5 F - 200 10, 15, 20 58.5
R - 300
BRCA1 4.0 F - 250 10, 10, 20 61.0
R - 250
CDH1 2.5 F - 200 10, 10, 20 63.5
R - 200




2.5 F - 300 10, 10, 20 70.0
R - 200
GSTP1 2.5 F - 200 10, 10, 20 64.5
R - 200
MAL 2.5 F - 200 10, 10, 20 59.0
R - 200
MGMT 4.0 F - 250 10, 20, 20 60.0
R - 250
MLH1 3.5 F - 200 10, 15, 20 59.0
R - 300
TP73 3.0 F - 300 10, 15, 20 55.0
R - 200
RARβ 3.0 F - 200 10, 10, 20 66.0
R - 300
RASSF1A 3.0 F - 300 15, 25, 20 65.0
R - 200
TWIST1 2.5 F - 200 10, 10, 20 52.0
R - 300
WIF1 3.0 F - 400 10, 20, 25 53.0
R - 400
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Given non-recurrence, these probabilities are:
Given recurrence, the probability of losing methylation
over the course of progression from primary to second-
ary tumour, γ has been estimated from the aCGH data
to be 0.05. On the other hand, the probability of gaining
methylation, which is expected to be higher as stated in
our assumption above, is estimated to be 2 γ
These tables are used to calculate the probabilities of
observing the methylation status of each gene as seen in
the methylation data. For example, if primary tumour A
is unmethylated and secondary tumour B is methylated
in gene i, then, according to the recurrence and non-
recurrence probability tables respectively,
Pr(xi|R) = 2γ(1 − pi) and Pr xijRð Þ ¼ pi 1−pið Þ
where xi represents the observed methylation status of
gene i in the MS-HRM data.








Two methods were then used to assess the LR values,
and subsequently the likelihood of recurrence: an empirical
approach and a Bayesian approach. The empirical ap-
proach unbiasedly utilises the methylation data to
statistically assess clonal relationship by generating a null
distribution of log-ratios representing the non-recurrence
population, without making pre-assumptions about the
likelihood of recurrence. However, since the strength of
this approach is limited by the small sample size and the
limited number of gene markers, more accurate classifica-
tions of de novo versus recurrence can be achieved by in-
corporating prior knowledge, hence the Bayesian approach.
Method 1: Bayesian inference
The key information required to calculate the likelihood
is the probability of each of the 13 genes being methyl-
ated in tumours. The average methylation frequency
of each gene in breast cancer was obtained from the lit-
erature [24–41]. The published results were reviewed and
selected by two individuals together (KTH and TM) for
the final decision (Additional file 1: Table S1). The aCGH
data generated in the study was also used in the calculat-
ing the log odds ratios.
When the chance between recurrence and non-
recurrence is not 50/50, then Bayesian inference was
used to calculate posterior LR, or PLR, based on the
prior knowledge of the chance of recurrence/non-recur-
rence. Applying Bayes’ theorem of conditional probabil-
ity on the above LR formula, we get
PLR ¼ loge
Pr Rð Þ
Pr Rð Þ þ LR
The prior probability of recurrence, i.e., Pr(R) were set
at 0.75 for ipsilateral samples and 0.145 for contralateral
samples. These values were obtained from literature that
used molecular assays of aCGH, LOH and p53 muta-
tions to differentiate recurrent and de novo tumours be-
tween the pair tumours [9, 12, 15, 16]. The frequency of
recurrent tumours found in ipsilateral tumour pairs was
about 75 % (ranged from 69–76 %), while the frequency
of recurrent tumour found in contralateral tumour pairs
was about 14.5 % (averaged value of 14 % and 15 %).
A sample can then be called recurrence or de novo de-
pending on the PLR value: PLR > 0 suggests recurrence,
while PLR < 0 suggests non-recurrence. These two inequal-
ities are equivalent to LR > −loge
Pr Rð Þ
Pr Rð Þ and LR < −loge
Pr Rð Þ
Pr Rð Þ respectively. Substituting in the probabilities of recur-
rences for ipsilateral samples gives LR > − 1.099 and LR < −
1.099. For contralateral samples, these are LR > 1.774 and
LR < 1.774 respectively.
Method 2: An empirical approach
The methylation data was also used to obtain an empirical
(i.e., prior knowledge was not used) null distribution of log
ratios representing the non-recurrence population. Cross
comparison between tumours from the 29 individuals gave
us 3248 (pairing up each tumour with those from other in-
dividuals gives 2 × 29 × 2 × 28 = 3248 combinations) pair-
wise comparisons of non-recurrent cases. The LRs
obtained from these comparisons form a null, or back-
ground, distribution from which P-values were calculated.
The plot follows an approximately normally distribution
(Additional file 2: Figure S1). P-values were calculated by
counting the number of cases in the null with LRs larger
than the LR of interest, and then dividing that number by
the total number of null cases. The P-value cut-off for in-
dicating the significance of recurrence was set at 0.05 in
the study (i.e., a P-value <0.05 indicates the second
tumour is likely to be clonally related to the first tumour).
Non-recurrence M (secondary) M (secondary)
M (primary) (1 − pi)
2 pi(1 − pi)
M (primary) pi(1 − pi) pi
2
Recurrence M (secondary) M (secondary)
M (primary) (1 − 2γ)(1 − pi) 2γ(1 − pi)
M (primary) γpi (1 − γ)pi
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Array comparative genomic hybridization (aCGH) data
generation and analyses
Genomic DNA (500 ng) from the same batch of tumour
DNA as used in methylation profiling was analysed
using the Agilent oligonucleotide array-bases CGH (4x
microarray) following the manufacturer’s instructions
(Agilent Technologies, Santa Clara, CA). In brief, gen-
omic DNA of samples and female reference DNA (a
normal control DNA) (Promega, Madison, WI) were
first fragmented for 30 s at 95 °C and 30 min at 95 °C re-
spectively, and then the reference and sample DNA were
labeled with ULS-Cy3 and ULS-Cy5 dye with the ratio
1 μL per 1 μg DNA, respectively. The non-reacted
Cy-ULS dyes were removed using Agilent KREApure
columns to reduce possible background noise for
array screening. Optimal Cy5 degree of labeling
(range between 0.75 % and 2.5 %) with a Cy3 minus
Cy5 range between 1 % and 2 % were used as a qual-
ity control guideline for sample labeling before hy-
bridizing to the array. Samples and references DNA
were hybridized on to the microarray at 65 °C for
40 h, and then washed and scanned. aCGH result
analyses was performed using the Partek® Genomics
Suite™ version 6.03 (Partek Inc., St. Louis, MO).
Statistical analysis
Statistical analyses were performed using GraphPad
Prism version 5.01 (GraphPad Software, San Diego, CA).
Comparisons of age and tumour size between ipsilateral
and contralateral groups were evaluated using the un-
paired Student’s t-test and nonparametric Mann–Whitney
U test, respectively. Fisher’s exact test was used to exam-
ine the association between ipsilateral and contralateral
groups with recurrent and de novo clonality. A two-tailed




The clinical and pathological features of the patients in
this study are summarised in Table 2. A trend was ob-
served for patients with ipsilateral tumours to develop
their primary tumours at an earlier median age than
patients with contralateral tumours (54 vs. 59 years), al-
though it was not significant at the 5 % level (P = 0.08).
The median age of onset for developing a second
tumour was also earlier for ipsilateral patients compared
with contralateral patients (59 vs. 68 years) (P = 0.07).
However, the median time interval for the second tu-
mours to develop was similar between ipsilateral patients
(4 years; range, 0–14 years) and contralateral patients
(5 years; range, 1–9 years) (P = 0.60) after the initial
breast tumour diagnosed.
DNA methylation patterns in ipsilateral and contralateral
sample pairs
Methylation of 13 cancer related genes was assessed in 16
ipsilateral and 13 contralateral breast cancer pairs using
MS-HRM (Table 3). In addition, promoter methylation of
MLH1 was assessed and treated as a negative methylation
control, as it is known to be unmethylated in breast
carcinomas.
Eleven cancer related genes were found to have
methylation (defined as more than 10 % methylation) in
at least some of the tumours: RASSF1A (64 %), TWIST1
(61 %), CDH13 (51 %), APC (50 %), MAL (35 %), GSTP1
(30 %), WIF1 (26 %), RARβ (19 %), BRCA1 (2 %),
CDKN2A (2 %) and TP73 (2 %). Two genes CDH1 and
MGMT were scored as unmethylated for all the samples
in this study as either no methylation or very low-level
methylation was detected. No promoter methylation of
MLH1 was found in any of the samples. Examples of the
MS-HRM results are shown in Fig. 1.
Determining clonal relationships using DNA
methylation profiling
DNA methylation patterns of the paired tumours were
compared to assess the likelihood that the second






Age of onset (years)
Primary
Median 54 59












Median (mm) 17.8 17
Range (mm) 6 – 50 10 – 40
P-value 0.711
Second tumour
Median (mm) 13.5 –
Range (mm) 0.3 – 75 –
aTime interval between first and second tumour onset
Huang et al. BMC Cancer  (2015) 15:669 Page 5 of 11
tumour had arisen from the first tumour. Some tumour
pairs, in particular ipsilateral pairs, showed very similar
DNA methylation patterns between the first and the sec-
ond tumours, whereas others showed markedly different
methylation patterns between the paired tumours. For
example, ipsilateral tumour pair 1 showed highly similar
methylation patterns, where all the genes that were
methylated in the primary tumour were also methylated
in the second tumour with additional methylation in
TP73. On the other hand, contralateral pair 2 showed
methylation of CDH13, MAL and TWIST1 in the first
tumour but no methylation of any of the marker panel
was found in the second tumour.
To objectively score whether both tumours are clonally
related in origin using DNA methylation patterns between
the paired tumours, log odds ratios were calculated as a
measurement of likelihood of recurrence. An empirical
approach was employed to assess the methylation data
against an estimated null distribution without making a
prior assumption on the likelihood of recurrence. Eight
percent of contralateral tumours and 38 % of
ipsilateral tumours were called recurrent with a sig-
nificance of P <0.05 using this approach. The much
higher proportion of ipsilateral cases with recurrence is
consistent with expectation, supporting the use of methy-
lation data as a tool for assessing clonal relationship.
We also applied Bayesian inference to determine the
clonal relationship between each pair of tumours based on
their methylation patterns. Posterior log-odds ratios, indi-
cating either positive or negative clonal relationships, were
calculated for each tumour pair using previously obtained
methylation frequency data for each of the genes
(Additional file 1: Table S1). The prior probabilities of a
tumour being recurrent for contralateral and ipsilateral
pairs were estimated to be 0.145 and 0.75 respectively.
Using Bayesian inference, it was determined that there
were eleven recurrent pairs (69 %) and five de novo pairs
(31 %) in ipsilateral tumours, compared with two recur-
rent pairs (15 %) and eleven de novo pairs (85 %) in
contralateral tumours (Table 4a). Using the empirical ap-
proach, it was determined that there were six recurrent
pairs (38 %) and ten de novo pairs (62 %) in ipsilateral
Table 3 DNA methylation profile by MS-HRM analysis in (A) 16 ipsilateral and (B) 13 contralateral breast carcinomas
A
B
The methylation frequency of each gene and the age onset of each sample are included in the table. Results of tumour origin of the paired tumours that scored
using MS-HRM and aCGH were stated on the left side of the table. Grey represents methylation and X represents samples that did not amplify
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tumours, compared with one recurrent pair (8 %) and
twelve de novo pairs (92 %) in contralateral tumours
(Table 4b). Although not all results analysed by both
approaches were concordant (79.3 %), in both cases the
results are consistent with the expectation that
ipsilateral tumours had a higher chance of being re-
current and contralateral tumours had a higher
chance of being de novo.
Comparison of genomic copy number in ipsilateral and
contralateral tumour pairs
Informative results using array comparative genomic
hybridization (aCGH) were obtained from 4 ipsilateral
pairs and 3 contralateral pairs whereas the DNA qual-
ity from the remaining 17 sample pairs was too poor
to achieve adequate labeling for array screening after
at least two attempts. In general, the aCGH data from
the second tumour was better quality with less noise
than the data from the primary tumour consistent
with the better quality of the DNA from the younger
FFPE tumour block.
The copy number was compared between each
tumour pair to determine the possible clonal
Fig. 1 Examples of MS-HRM analysis of a APC, b MAL, c CDH13 and d RARβ genes in ipsilateral sample 1. The figure shows negative first derivative (Tm)
melting curves of the MS-HRM profiles. MS-HRM differentiates the methylated DNA from the unmethylated DNA based on the sequence-dependent
thermostability. Fully methylated samples melt later than the unmethylated WGA samples as there are cytosines retained in the sequence after bisulfite
modification. Standards with different methylation levels (10 %, 25 % and 50 %) were prepared by mixing the fully methylated DNA with fully
unmethylated DNA. Ipsilateral sample 1A represents the first tumour and 1B represents the second tumour
Table 4 Summary of deduced clonal origins of ipsilateral and
contralateral tumour pairs using (a) a Bayesian inference
approach and (b) an empirical approach
Recurrent De novo Total
a
Ipsilateral 11 (69 %) 5 (31 %) 16 (100 %)
Contralateral 2 (15 %) 11 (85 %) 13 (100 %)
b
Ipsilateral 6 (38 %) 10 (62 %) 16 (100 %)
Contralateral 1 (8 %) 12 (92 %) 13 (100 %)
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relationship. Of the seven sample pairs, two of the sec-
ond tumours were determined as de novo (one from ip-
silateral pairs and one from contralateral pairs) and five
of the second tumours were determined as recurrent
(three from ipsilateral pairs and two from contralateral
pairs). Array CGH results are summarised in Table 5.
Examples of aCGH results (ipsilateral pair 12 and
contralateral pair 3) are shown in Fig. 2. In ipsilateral
pair 12, the gains of chromosome 1q, part of 11q (in-
cluding the cyclinD1 locus on11q13), 12p, part of 12q
and 19 and losses of chromosome 6q, part of 11q,
12q and 13 were found in the primary tumour
(Fig. 2a, b). These gains and losses were also found in
the second tumour with the similar pattern or at the
same position. Hence, the second tumour is highly
likely to be recurrent from the primary. In contralat-
eral pair 3, there were several gains and losses found
in the primary tumour that was not found in the sec-
ond tumour, such as gain of chromosome 11p and
part of 17q and loss of chromosome 18. It is less
likely for tumours of the same clonal origin to have
different genomic copy number. Thus, the second
tumour is likely to be a de novo tumour (Fig. 2c, d).
Comparison between methylation profile and
CGH microarray
The best differentiation between de novo and recurrent
tumours up to now has been given by allelic imbalance
profiles. Therefore, the clonal origin results determined
by aCGH was used to reflect the actual tumour origin of
the tumour pairs in order to calculate the predictive
values of sensitivity, specificity, positive predictive value
and negative predictive value for methylation results
scored by both algorithms (Table 6).
We compared the clonal results of the tumour pairs
determined using methylation profiling and aCGH
data. A discrepancy was seen in three out of seven
tumour pairs when comparing aCGH prediction to
the methylation profiling prediction using the Bayesian in-
ference formula.
Discussion
Several types of molecular analyses have been previously
used to assess the clonal relationships between ipsilateral
and contralateral breast cancers. These include assays for
genomic imbalance (by aCGH) and TP53 mutation
screening [3, 10, 15, 16]. We performed DNA methylation
profiling of a set of genes commonly methylated in breast
cancer to assess if this is of use to determine whether the
first and the second tumour are clonally related.
It has been shown that individual breast cancers have
a distinct profile of methylated genes [42]. Thus, we hy-
pothesized that DNA methylation profiling either by it-
self or combined with genetic alterations using aCGH
therefore might be a useful tool to distinguish between
de novo and recurrent tumours.
The DNA methylation frequency of genes studied in
our tumour cohort was compared with what has been
reported in the literature for breast cancers (Additional
file 1: Table S1). For example, RASSF1A, CDH13 and
Table 5 Gene copy number variation results from aCGH on seven sample pairs
Sample Loss of chromosome Gain of chromosome Recurrent/De novo Note
Ipsilateral 2 First tumour Likely to be de novo
Second tumour 2p, 3p (partial), 7q, 8q, 10p (partial), 19p
Ipsilateral 6 First tumour 3p (partial) 17q (partial) Likely to be recurrent The second tumour still
retains the variation of the
primary tumour, especially
gain of 17q12 (Her2)
Second tumour 3p (partial), 4q, 8p,
9p, 10p, 11q, 13, 18
1q (partial), 12p, 14p,
17q (partial), 19p
Ipsilateral 11 First tumour 5q (partial), 8q (partial), 17q (partial) Recurrent Whole genome variation
of primary and second
tumour overlaid exactlySecond tumour 5q (partial), 8q (partial), 17q (partial)
Ipsilateral 12 First tumour 6q, 11q, 12q, 13 1q, 11p (partial), 12p,
12q (partial), 19
Likely to be recurrent Similar overall patterns in
chromosome 11, 12 and 19
Second tumour 2q (partial), 3p (partial),
4, 6q, 7q (partial), 11q,
12q, 13
1q, 11p (partial), 12p,
12q (partial), 15, 19
Contralateral 3 First tumour 6q, 11q, 18 1q, 11p, 17q (partial) Likely to be de novo
Second tumour 6q, 16q, 22 1q, 16p, Xq
Contralateral 10 First tumour 3p 6p, 8q Likely to be recurrent Similar overall patterns,
especially in chromosome 8,
21 and 22Second tumour 6p, 8q
Contralateral 13 First tumour 3p (partial), 8q, 11q (partial) Likely to be recurrent
Second tumour 3p (partial), 8q, 11q (partial)
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RARβ have been reported to be frequently methylated in
breast cancer (average frequency of 71 %, 49 % and 21 %
respectively, Additional file 1: Table S1), which is similar
to our results of 64 %, 51 % and 19 % methylation in both
ipsilateral and contralateral pairs respectively. However
discrepant values such as TWIST1 61 % vs 26 %, WIF1
28 % vs 65 % and CDH1 0 % vs 28 % most likely represent
variation in the region being examined and methodology.
Interestingly, there was only one sample that was methyl-
ated for BRCA1 (2 %), a frequency about ten times less
than what is typically identified in the literature [26, 43]
that is likely due to bias from a relatively small series.
Although CDH1 has been reported to be frequently
methylated in breast tumours and suggested as a bio-
marker for breast cancer, we did not identify any methy-
lation of CDH1. Different methodologies have been used
to detect the methylation status of CDH1 in breast can-
cers and a wide range of methylation frequencies in
breast cancers has been reported (range from 1 to 23 %).
However, our result was consistent with both our previ-
ous MS-HRM data (1 %: unpublished) and Feng et al.
who employed bisulfite pyrosequencing [31] and re-
ported methylation at low levels in both malignant and
normal breast tissue.
The methods we have used eliminate the biases intrin-
sic to traditional ways of determining tumour origins,
which often involve subjective input from a pathologist
(operator) and which have shown to be inaccurate. How-
ever, the accuracy of our methods is dependent on a
prior knowledge on methylation frequencies (in the case of
Bayesian approach) or the number of samples from which
a null distribution is estimated (empirical approach).
Nevertheless, while both methods had similar NPV, the
empirical approach showed a better representation and
PPV suggesting is the better predictor for tumor related-
ness based on methylation profiling. However it must be
noted that this conclusion is based on a small number of
tumors and gene markers.
Nonetheless, this study has demonstrated by methyla-
tion profiling, that a proportion of subsequent breast
tumours share similar methylation profiles with the first
tumour indicating that these tumours are likely to be
clonally related. As also anticipated, ipsilateral tumours
have a higher probability of being recurrent compared
with contralateral tumours, which had a higher chance of
being de novo tumours. These results are consistent with
reports in the literature using different methodologies that
ipsilateral breast cancers mostly arise from a single breast
cancer whereas contralateral breast cancers frequently
represent different primary breast cancers [3, 15, 16].
Fig. 2 Examples of genomic aCGH profiles of a recurrent ipsilateral pair 12 with a whole genome profile and b individual chromosomes of 9, 10,
11, 12, 17, 18, 19 and 20; and a de novo contralateral pair 3 with c whole genome profile and d individual chromosomes of 1, 8, 11, 13, 16, 17
and 18. Primary tumour (green) on top and the second tumour (purple) on bottom. Most informative areas were highlighted by the solid box
Table 6 Predictive values of using methylation profiling with
different algorithms to distinguish tumour origins (n = 7)
Methylation
Recurrent De novo
aCGH Recurrent 3 2 Sn = 0.60 (3/5)
De novo 1 1 Sp = 0.50 (1/2)
PPV = 0.75 (3/4) NPV = 0.33 (1/3)
Results were scored using Bayesian inference approach
NPV negative predictive value, PPV positive predictive value, Sn sensitivity,
Sp specificity
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Based on previous studies, approximately 75 % of sec-
ond tumours are clonally related to the initial carcin-
oma in ipsilateral cases [9, 12, 16], compared to only
~15 % of contralateral [15, 16]. The frequency of re-
current and de novo tumours found in ipsilateral and
contralateral cases reported in the literature are very close
to the methylation results scored using the Bayesian infer-
ence approach in this paper. However, the recurrence
rates called significant by our approach are lower than
expected from the literature (15 % and 75 %).
Array CGH was used to validate the clonal predictions
based on methylation but only a small number of samples
were assessable by aCGH due to poor DNA quality.
Nevertheless, informative aCGH results were obtained for
seven sample pairs. In general, the later onset tumours
had frequent additional genomic copy number alterations
consistent with continued clonal evolution. Frequently al-
tered genes in breast cancer can be useful as clinical
markers, such as HER2 or CCND1, which allows the iden-
tification of the clonal relationship in a tumour pair. For
example, gain of HER2 (17q12) was found in both primary
and second tumours of ipsilateral pair 6, and gain of
CCND1 (11q13) was found in both primary and second
tumours of ipsilateral 12.
Genome-wide DNA copy number variation in tumours
has been widely studied and used as a reliable tool to dif-
ferentiate between tumours. However, the applicability of
the technique to FFPE DNA is limited by DNA fragmen-
tation, which can preclude generation of interpretable
data. It is for this reason that we developed assays using
MS-HRM that can be designed to meet the challenges as-
sociated with analysis of poor quality FFPE samples.
Conclusions
In summary, DNA methylation profiling using method-
ology compatible with degraded DNA has potential to
be used as a diagnostic tool in improving the clinical
decisions to differentiate recurrences from a second
de novo tumour in FFPE samples.
Additional files
Additional file 1: Table S1. Comparison of DNA methylation frequency
of genes screened in breast carcinomas with the methylation frequency
in literature. (DOCX 100 kb)
Additional file 2: Figure S1. Normally distributed test statistics
generated using empirical null distribution of LRs. N = 3248 and
bandwidth = 0.8926. (TIFF 115 kb)
Abbreviations
aCGH: array comparative genomic hybridization; LOH: Loss of heterozygosity;
FFPE: Formalin-fixed paraffin-embedded; WGA: Whole-genome amplification;
MS-HRM: Methylation-sensitive high-resolution melting; PPV: Positive
predictive value; NPV: Negative predictive value.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KTH participated in the designing of DNA methylation and aCGH experiments,
performed the experiments, DNA methylation and aCGH data analysis and
interpretation, drafted and revised the manuscript. TM participated in analyzing
and interpreting DNA methylation data. JL performed statistical analysis. EAT
assisted with writing of the manuscript. Samples and clinicopathological data
were collected by EKAM and PHG. SEB helped in performing aCGH experiment.
IGC participated in analyzing and interpreting aCGH data. TPS contributed in
statistical analysis. AD participated in the designing of the DNA methylation
experiments and helped to analyse the data, and assisted with the writing of
the manuscript. SBF conceptualised the study, contributed to manuscript
writing and supervised the work. All authors have read and approved the
final manuscript.
Acknowledgements
We wish to thank members of the Molecular Pathology Research and
Development group in Peter MacCallum Cancer Centre for their help and
support. We would like to thank Dr. Christoph Bock for helpful comments on
analysis of the methylation results. This work was funded by grants from the
Victorian Breast Cancer Research Consortium, Cancer Australia, the National
Breast Cancer Foundation of Australia (Collaborative Research Program) and
the Cancer Council of Victoria.
Author details
1Molecular Pathology Research and Development Laboratory, Department of
Pathology, Peter MacCallum Cancer Centre, St. Andrew’s Place, East
Melbourne, VIC 3002, Australia. 2Department of Pathology and Sir Peter
MacCallum Department of Oncology, University of Melbourne, Grattan Street,
Parkville, VIC 3010, Australia. 3Translational Genomics and Epigenomics
Laboratory, Olivia Newton-John Cancer Research Institute, Studley Road,
Heidelberg, VIC 3084, Australia. 4Bioinformatics, Peter MacCallum Cancer
Centre, St. Andrew’s Place, East Melbourne, VIC 3002, Australia. 5South
Eastern Area Laboratory Service (SEALS), St. George Hospital, Gary Street,
Kogarah, NSW 2217, Australia. 6The Kinghorn Cancer Centre & Garvan
Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW 2010,
Australia. 7School of Medicine and Health Sciences, University of Western
Sydney, Narellan Road, Campbelltown, NSW 2560, Australia. 8Faculty of
Medicine, University of NSW, High Street, Kensington, NSW 2052, Australia.
9VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, St.
Andrew’s Place, East Melbourne, VIC 3002, Australia. 10Bioinformatics Division,
Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville,
VIC 3052, Australia. 11School of Cancer Medicine, La Trobe University,
Bundoora, VIC 3084, Australia.
Received: 12 December 2014 Accepted: 1 October 2015
References
1. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral
breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:855–61.
2. Goldstein NS, Kestin L, Vicini F. Factors associated with ipsilateral breast
failure and distant metastases in patients with invasive breast carcinoma
treated with breast-conserving therapy. A clinicopathologic study of 607
neoplasms from 583 patients. Am J Clin Pathol. 2003;120:500–27.
3. Imyanitov EN, Hanson KP. Molecular pathogenesis of bilateral breast cancer.
Cancer Lett. 2003;191:1–7.
4. Ziogas D, Roukos DH. Genetics and personal genomics for personalized
breast cancer surgery: progress and challenges in research and clinical
practice. Ann Surg Oncol. 2009;16:1771–82.
5. Hameed O, Pfeifer JD. Classifying "recurrent" breast cancer: lost
heterozygosity found. Am J Clin Pathol. 2005;123:641–3.
6. Haffty BG, Reiss M, Beinfield M, Fischer D, Ward B, McKhann C. Ipsilateral
breast tumor recurrence as a predictor of distant disease: implications for
systemic therapy at the time of local relapse. J Clin Oncol. 1996;14:52–7.
7. Elkhuizen PH, van de Vijver MJ, Hermans J, Zonderland HM, van de Velde
CJ, Leer JW. Local recurrence after breast-conserving therapy for invasive
breast cancer: high incidence in young patients and association with poor
survival. Int J Radiat Oncol Biol Phys. 1998;40:859–67.
Huang et al. BMC Cancer  (2015) 15:669 Page 10 of 11
8. Huang E, Buchholz TA, Meric F, Krishnamurthy S, Mirza NQ, Ames FC, et al.
Classifying local disease recurrences after breast conservation therapy based
on location and histology: new primary tumors have more favorable
outcomes than true local disease recurrences. Cancer. 2002;95:2059–67.
9. Goldstein NS, Vicini FA, Hunter S, Odish E, Forbes S, Kraus D, et al. Molecular
clonality determination of ipsilateral recurrence of invasive breast
carcinomas after breast-conserving therapy: comparison with clinical and
biologic factors. Am J Clin Pathol. 2005;123:679–89.
10. Saad RS, Denning KL, Finkelstein SD, Liu Y, Pereira TC, Lin X, et al. Diagnostic
and prognostic utility of molecular markers in synchronous bilateral breast
carcinoma. Mod Pathol. 2008;21:1200–7.
11. Goldstein NS, Vicini FA, Hunter S, Odish E, Forbes S, Kestin LL. Molecular
clonality relationships in initial carcinomas, ipsilateral breast failures, and
distant metastases in patients treated with breast-conserving therapy:
evidence suggesting that some distant metastases are derived from
ipsilateral breast failures and that metastases can metastasize. Am J Clin
Pathol. 2005;124:49–57.
12. Vicini FA, Antonucci JV, Goldstein N, Wallace M, Kestin L, Krauss D, et al. The
use of molecular assays to establish definitively the clonality of ipsilateral
breast tumor recurrences and patterns of in-breast failure in patients with
early-stage breast cancer treated with breast-conserving therapy. Cancer.
2007;109:1264–72.
13. Kuligina E, Grigoriev MY, Suspitsin EN, Buslov KG, Zaitseva OA, Yatsuk OS, et
al. Microsatellite instability analysis of bilateral breast tumors suggests
treatment-related origin of some contralateral malignancies. J Cancer Res
Clin Oncol. 2007;133:57–64.
14. Banelli B, Casciano I, Di Vinci A, Gatteschi B, Levaggi A, Carli F, et al.
Pathological and molecular characteristics distinguishing contralateral
metastatic from new primary breast cancer. Ann Oncol. 2009.
15. Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S,
et al. Contralateral breast cancer: molecular differentiation between
metastasis and second primary cancer. Breast Cancer Res Treat. 2001;67:1–8.
16. Teixeira MR, Ribeiro FR, Torres L, Pandis N, Andersen JA, Lothe RA, et al.
Assessment of clonal relationships in ipsilateral and bilateral multiple breast
carcinomas by comparative genomic hybridisation and hierarchical
clustering analysis. Br J Cancer. 2004;91:775–82.
17. Herman JG, Baylin SB. Mechanisms of disease: Gene silencing in cancer in
association with promoter hypermethylation. New Engl J Med. 2003;349:2042–54.
18. Kristensen LS, Mikeska T, Krypuy M, Dobrovic A. Sensitive Melting Analysis after
Real Time-Methylation Specific PCR (SMART-MSP): high-throughput and probe-
free quantitative DNA methylation detection. Nucleic Acids Res. 2008;36.
19. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting
(MS-HRM): a new approach for sensitive and high-throughput assessment
of methylation. Nucleic Acids Res. 2007;35.
20. Candiloro IL, Mikeska T, Hokland P, Dobrovic A. Rapid analysis of
heterogeneously methylated DNA using digital methylation-sensitive high
resolution melting: application to the CDKN2B (p15) gene. Epigenetics
Chromatin. 2008;1(1):7.
21. Huang KT, Dobrovic A, Yan M, Karim RZ, Lee CS, Lakhani SR, et al. DNA
methylation profiling of phyllodes and fibroadenoma tumours of the breast.
Breast Cancer Res Treat. 2010;124(2):555–65.
22. Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, et al.
Constitutional methylation of the BRCA1 promoter is specifically associated
with BRCA1 mutation-associated pathology in early-onset breast cancer.
Cancer Prev Res (Phila). 2011;4:23–33.
23. Wojdacz TK, Hansen LL, Dobrovic A. A new approach to primer design for
the control of PCR bias in methylation studies. BMC Res Notes. 2008;1:54.
24. Pasquali L, Bedeir A, Ringquist S, Styche A, Bhargava R, Trucco G.
Quantification of CpG island methylation in progressive breast lesions from
normal to invasive carcinoma. Cancer Lett. 2007;257:136–44.
25. Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, et al. Inactivation of Wnt
inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common
event in breast cancer. Carcinogenesis. 2006;27:1341–8.
26. Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A. Tumour-specific
distribution of BRCA1 promoter region methylation supports a pathogenetic
role in breast and ovarian cancer. Carcinogenesis. 2000;21:147–51.
27. Cho YH, Yazici H, Wu HC, Terry MB, Gonzalez K, Qu M, et al. Aberrant
promoter hypermethylation and genomic hypomethylation in tumor,
adjacent normal tissues and blood from breast cancer patients.
Anticancer Res. 2010;30:2489–96.
28. Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 Gene in Sporadic
Breast Cancer. Cancer Res. 1997;57:3347–50.
29. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile
of human cancer. Cancer Res. 2001;61:3225–9.
30. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al.
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and
ovarian tumors. J Natl Cancer Inst. 2000;92:564–9.
31. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, et al. Correlation
between CpG methylation profiles and hormone receptor status in breast
cancers. Breast Cancer Res. 2007;9:R57.
32. Gort EH, Suijkerbuijk KP, Roothaan SM, Raman V, Vooijs M, van der Wall E, et
al. Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and
immunohistochemical expression of TWIST1 in breast cancer. Cancer
Epidemiol Biomarkers Prev. 2008;17:3325–30.
33. Horne HN, Lee PS, Murphy SK, Alonso MA, Olson Jr JA, Marks JR. Inactivation
of the MAL gene in breast cancer is a common event that predicts benefit
from adjuvant chemotherapy. Mol Cancer Res. 2009;7:199–209.
34. Jin Z, Tamura G, Tsuchiya T, Sakata K, Kashiwaba M, Osakabe M, et al.
Adenomatous polyposis coli (APC) gene promoter hypermethylation in
primary breast cancers. Br J Cancer. 2001;85:69–73.
35. Prasad CP, Mirza S, Sharma G, Prashad R, DattaGupta S, Rath G, et al.
Epigenetic alterations of CDH1 and APC genes: relationship with activation
of Wnt/beta-catenin pathway in invasive ductal carcinoma of breast.
Life Sci. 2008;83:318–25.
36. Ronneberg JA, Tost J, Solvang HK, Alnaes GI, Johansen FE, Brendeford EM,
et al. GSTP1 promoter haplotypes affect DNA methylation levels and
promoter activity in breast carcinomas. Cancer Res. 2008;68:5562–71.
37. Sharma G, Mirza S, Yang YH, Parshad R, Hazrah P, Datta Gupta S, et al.
Prognostic relevance of promoter hypermethylation of multiple genes in
breast cancer patients. Cell Oncol. 2009;31:487–500.
38. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM,
Gilcrease M, et al. Loss of expression and aberrant methylation of the
CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res.
2001;61:4556–60.
39. Veeck J, Wild PJ, Fuchs T, Schuffler PJ, Hartmann A, Knuchel R, et al. Prognostic
relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter
methylation in human breast cancer. BMC Cancer. 2009;9:217.
40. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, et al. BRCA1 promoter
methylation in sporadic breast cancer is associated with reduced BRCA1 copy
number and chromosome 17 aneusomy. Cancer Res. 2005;65:10692–9.
41. Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, et al. Estrogen
receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct
subsets of sporadic breast cancers. Breast Cancer Res Treat. 2008;111:113–20.
42. Van der Auwera I, Yu W, Suo L, Van Neste L, van Dam P, Van Marck EA, et
al. Array-based DNA methylation profiling for breast cancer subtype
discrimination. PLoS One. 2010;5, e12616.
43. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1
promoter region in sporadic breast and ovarian cancer: correlation with
disease characteristics. Oncogene. 1999;18:1957–65.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Huang et al. BMC Cancer  (2015) 15:669 Page 11 of 11
